Darae Strategic Commercialization Center Co., Ltd. (CEOs Bae Sun-gu and Kim Jeong-guk), a leading expert in introduction en bourse par la technologie consulting, and RudaCure Inc. (PDG Yongho Kim), a drug developer targeting trouble sensoriel diseases, have solidified their strategic partenariat.
On the 4th, the two companies signed an 'MOU for IP Portfolio Strategy Development and Technology-Based Listing Evaluation Consulting for RudaCure Inc.'
Grâce à cela MOU and investissement, Darae Strategic Commercialization Center will provide complet consulting to RudaCure Inc.—which is planning a introduction en bourse par la technologie—notamment mock evaluations for introduction en bourse par la technologie, IP portefeuille and R&D strategy, and investissement support, afin de help RudaCure Inc. avec succès achieve a stable introduction en bourse par la technologie with its excellent technologies and drugs.
Darae Strategic Commercialization Center holds the highest reputation in the pharmaceutique and bio consulting industrie, consulting dozens of pharmaceutique and bio companies each year. It provides a wide range of consulting services notamment introduction en bourse par la technologie consulting, IP consulting, R&D strategy, and technology valuation, and is also actively involved as an accelerator and investisseur. Récemment, l'entreprise has been concentrating its capabilities on introduction en bourse par la technologie consulting for pharmaceutique and bio companies.
RudaCure Inc. has already had licence experience with traitement de la sécheresse oculaires and traitement des lésions cornéenness in 2021 and 2023, and is actuellement developing a best-in-class powerful analgésique non narcotique. L'entreprise is developing innovant drugs for divers intractable diseases targeting GTPase and canaux ioniques, and is actively conducting research on psoriasis, atopic dermatitis, and anticancer agents. As a bioventure company pursuing continuous growth through recherche conjointe and co-développement with national and international entreprises pharmaceutiques, RudaCure is well-positioned for future expansion.
RudaCure Inc. le PDG Yongho Kim a déclaré : "Through substantive mutual cooperation with Darae Strategic Commercialization Center, with whom we have built a relationship over the past three years, we will grow into a bioventure company with even stronger propriété intellectuelle and differentiated technologies à l'avenir," expressing expectations for the strategic collaboration.
RudaCure Inc. is actuellement identifying compounds effective for chemotherapy-induced and cancer-related pain, and is preparing to present the technology at the 2023 ASCO conference. As a member of the essai clinique delegation, l'entreprise plans to simultaneously engage in exchange and technology promotion regarding anticancer essais cliniques on-site.
Yakup Sinmun: RudaCure "Formally begins preparations for technology-based IPO listing"